Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay

Marlyn J. Mayo, Julie Parkes, Beverley Adams-Huet, Burton Combes, A. S. Mills, Rodney S. Markin, Raphael Rubin, Donald Wheeler, Melissa Contos, A. B. West, Sandra Saldana, Yonas Getachew, Robert Butsch, Velimir Luketic, Marion Peters, Adrian Di Bisceglie, Nathan Bass, John Lake, Thomas Boyer, Enrique MartinezJames Boyer, Guadalupe Garcia-Tsao, David Barnes, William M. Rosenberg

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Primary biliary cirrhosis (PBC) is sometimes diagnosed based on a positive antimitochondrial antibody in the appropriate clinical setting without a liver biopsy. Although a liver biopsy can assess the extent of liver fibrosis and provide prognostic information, serum fibrosis markers avoid biopsy complications and sampling error and provide results as a continuous variable, which may be more precise than categorical histological stages. The current study was undertaken to evaluate serum fibrosis markers as predictors of clinical progression in a large cohort of PBC patients. Serial liver biopsy specimens and serum samples were collected every 2 years in 161 PBC subjects for a median of 7.3 years. Clinical progression was defined as development of one or more of the following events: varices, variceal bleed, ascites, encephalopathy, liver transplantation, or liver-related death. Serum hyaluronic acid, tissue inhibitor of metalloproteinase 1, and procollagen III aminopeptide were measured and entered into the previously validated enhanced liver fibrosis (ELF) algorithm. The ability of ELF, histological fibrosis, bilirubin, Model for End-Stage Liver Disease (MELD), and Mayo Risk Score to differentiate between individuals who would experience a clinical event from those who would not was evaluated at different time points. Event-free survival was significantly lower in those with high baseline ELF. Each 1-point increase in ELF was associated with a threefold increase in future complications. The prognostic performance of all tests was similar when performed close to the time of the first event. However, at earlier times in the disease process (4 and 6 years before the first event), the prognostic performance of ELF was significantly better than MELD or Mayo R score. Conclusion: The ELF algorithm is a highly accurate noninvasive measure of PBC disease severity that provides useful long-term prognostic information. Copyrtght

Original languageEnglish (US)
Pages (from-to)1549-1557
Number of pages9
JournalHepatology
Volume48
Issue number5
DOIs
StatePublished - Nov 2008

Fingerprint

Biliary Liver Cirrhosis
Liver Cirrhosis
Serum
Biopsy
End Stage Liver Disease
Fibrosis
Liver
Biomarkers
Procollagen
Tissue Inhibitor of Metalloproteinase-1
Selection Bias
Varicose Veins
Brain Diseases
Hyaluronic Acid
Bilirubin
Ascites
Liver Transplantation
Disease-Free Survival
Antibodies

ASJC Scopus subject areas

  • Hepatology
  • Medicine(all)

Cite this

Mayo, M. J., Parkes, J., Adams-Huet, B., Combes, B., Mills, A. S., Markin, R. S., ... Rosenberg, W. M. (2008). Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology, 48(5), 1549-1557. https://doi.org/10.1002/hep.22517

Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. / Mayo, Marlyn J.; Parkes, Julie; Adams-Huet, Beverley; Combes, Burton; Mills, A. S.; Markin, Rodney S.; Rubin, Raphael; Wheeler, Donald; Contos, Melissa; West, A. B.; Saldana, Sandra; Getachew, Yonas; Butsch, Robert; Luketic, Velimir; Peters, Marion; Di Bisceglie, Adrian; Bass, Nathan; Lake, John; Boyer, Thomas; Martinez, Enrique; Boyer, James; Garcia-Tsao, Guadalupe; Barnes, David; Rosenberg, William M.

In: Hepatology, Vol. 48, No. 5, 11.2008, p. 1549-1557.

Research output: Contribution to journalArticle

Mayo, MJ, Parkes, J, Adams-Huet, B, Combes, B, Mills, AS, Markin, RS, Rubin, R, Wheeler, D, Contos, M, West, AB, Saldana, S, Getachew, Y, Butsch, R, Luketic, V, Peters, M, Di Bisceglie, A, Bass, N, Lake, J, Boyer, T, Martinez, E, Boyer, J, Garcia-Tsao, G, Barnes, D & Rosenberg, WM 2008, 'Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay', Hepatology, vol. 48, no. 5, pp. 1549-1557. https://doi.org/10.1002/hep.22517
Mayo, Marlyn J. ; Parkes, Julie ; Adams-Huet, Beverley ; Combes, Burton ; Mills, A. S. ; Markin, Rodney S. ; Rubin, Raphael ; Wheeler, Donald ; Contos, Melissa ; West, A. B. ; Saldana, Sandra ; Getachew, Yonas ; Butsch, Robert ; Luketic, Velimir ; Peters, Marion ; Di Bisceglie, Adrian ; Bass, Nathan ; Lake, John ; Boyer, Thomas ; Martinez, Enrique ; Boyer, James ; Garcia-Tsao, Guadalupe ; Barnes, David ; Rosenberg, William M. / Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. In: Hepatology. 2008 ; Vol. 48, No. 5. pp. 1549-1557.
@article{24d0ede5a6bb411db6f412e2592b2b9c,
title = "Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay",
abstract = "Primary biliary cirrhosis (PBC) is sometimes diagnosed based on a positive antimitochondrial antibody in the appropriate clinical setting without a liver biopsy. Although a liver biopsy can assess the extent of liver fibrosis and provide prognostic information, serum fibrosis markers avoid biopsy complications and sampling error and provide results as a continuous variable, which may be more precise than categorical histological stages. The current study was undertaken to evaluate serum fibrosis markers as predictors of clinical progression in a large cohort of PBC patients. Serial liver biopsy specimens and serum samples were collected every 2 years in 161 PBC subjects for a median of 7.3 years. Clinical progression was defined as development of one or more of the following events: varices, variceal bleed, ascites, encephalopathy, liver transplantation, or liver-related death. Serum hyaluronic acid, tissue inhibitor of metalloproteinase 1, and procollagen III aminopeptide were measured and entered into the previously validated enhanced liver fibrosis (ELF) algorithm. The ability of ELF, histological fibrosis, bilirubin, Model for End-Stage Liver Disease (MELD), and Mayo Risk Score to differentiate between individuals who would experience a clinical event from those who would not was evaluated at different time points. Event-free survival was significantly lower in those with high baseline ELF. Each 1-point increase in ELF was associated with a threefold increase in future complications. The prognostic performance of all tests was similar when performed close to the time of the first event. However, at earlier times in the disease process (4 and 6 years before the first event), the prognostic performance of ELF was significantly better than MELD or Mayo R score. Conclusion: The ELF algorithm is a highly accurate noninvasive measure of PBC disease severity that provides useful long-term prognostic information. Copyrtght",
author = "Mayo, {Marlyn J.} and Julie Parkes and Beverley Adams-Huet and Burton Combes and Mills, {A. S.} and Markin, {Rodney S.} and Raphael Rubin and Donald Wheeler and Melissa Contos and West, {A. B.} and Sandra Saldana and Yonas Getachew and Robert Butsch and Velimir Luketic and Marion Peters and {Di Bisceglie}, Adrian and Nathan Bass and John Lake and Thomas Boyer and Enrique Martinez and James Boyer and Guadalupe Garcia-Tsao and David Barnes and Rosenberg, {William M.}",
year = "2008",
month = "11",
doi = "10.1002/hep.22517",
language = "English (US)",
volume = "48",
pages = "1549--1557",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay

AU - Mayo, Marlyn J.

AU - Parkes, Julie

AU - Adams-Huet, Beverley

AU - Combes, Burton

AU - Mills, A. S.

AU - Markin, Rodney S.

AU - Rubin, Raphael

AU - Wheeler, Donald

AU - Contos, Melissa

AU - West, A. B.

AU - Saldana, Sandra

AU - Getachew, Yonas

AU - Butsch, Robert

AU - Luketic, Velimir

AU - Peters, Marion

AU - Di Bisceglie, Adrian

AU - Bass, Nathan

AU - Lake, John

AU - Boyer, Thomas

AU - Martinez, Enrique

AU - Boyer, James

AU - Garcia-Tsao, Guadalupe

AU - Barnes, David

AU - Rosenberg, William M.

PY - 2008/11

Y1 - 2008/11

N2 - Primary biliary cirrhosis (PBC) is sometimes diagnosed based on a positive antimitochondrial antibody in the appropriate clinical setting without a liver biopsy. Although a liver biopsy can assess the extent of liver fibrosis and provide prognostic information, serum fibrosis markers avoid biopsy complications and sampling error and provide results as a continuous variable, which may be more precise than categorical histological stages. The current study was undertaken to evaluate serum fibrosis markers as predictors of clinical progression in a large cohort of PBC patients. Serial liver biopsy specimens and serum samples were collected every 2 years in 161 PBC subjects for a median of 7.3 years. Clinical progression was defined as development of one or more of the following events: varices, variceal bleed, ascites, encephalopathy, liver transplantation, or liver-related death. Serum hyaluronic acid, tissue inhibitor of metalloproteinase 1, and procollagen III aminopeptide were measured and entered into the previously validated enhanced liver fibrosis (ELF) algorithm. The ability of ELF, histological fibrosis, bilirubin, Model for End-Stage Liver Disease (MELD), and Mayo Risk Score to differentiate between individuals who would experience a clinical event from those who would not was evaluated at different time points. Event-free survival was significantly lower in those with high baseline ELF. Each 1-point increase in ELF was associated with a threefold increase in future complications. The prognostic performance of all tests was similar when performed close to the time of the first event. However, at earlier times in the disease process (4 and 6 years before the first event), the prognostic performance of ELF was significantly better than MELD or Mayo R score. Conclusion: The ELF algorithm is a highly accurate noninvasive measure of PBC disease severity that provides useful long-term prognostic information. Copyrtght

AB - Primary biliary cirrhosis (PBC) is sometimes diagnosed based on a positive antimitochondrial antibody in the appropriate clinical setting without a liver biopsy. Although a liver biopsy can assess the extent of liver fibrosis and provide prognostic information, serum fibrosis markers avoid biopsy complications and sampling error and provide results as a continuous variable, which may be more precise than categorical histological stages. The current study was undertaken to evaluate serum fibrosis markers as predictors of clinical progression in a large cohort of PBC patients. Serial liver biopsy specimens and serum samples were collected every 2 years in 161 PBC subjects for a median of 7.3 years. Clinical progression was defined as development of one or more of the following events: varices, variceal bleed, ascites, encephalopathy, liver transplantation, or liver-related death. Serum hyaluronic acid, tissue inhibitor of metalloproteinase 1, and procollagen III aminopeptide were measured and entered into the previously validated enhanced liver fibrosis (ELF) algorithm. The ability of ELF, histological fibrosis, bilirubin, Model for End-Stage Liver Disease (MELD), and Mayo Risk Score to differentiate between individuals who would experience a clinical event from those who would not was evaluated at different time points. Event-free survival was significantly lower in those with high baseline ELF. Each 1-point increase in ELF was associated with a threefold increase in future complications. The prognostic performance of all tests was similar when performed close to the time of the first event. However, at earlier times in the disease process (4 and 6 years before the first event), the prognostic performance of ELF was significantly better than MELD or Mayo R score. Conclusion: The ELF algorithm is a highly accurate noninvasive measure of PBC disease severity that provides useful long-term prognostic information. Copyrtght

UR - http://www.scopus.com/inward/record.url?scp=56149116412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56149116412&partnerID=8YFLogxK

U2 - 10.1002/hep.22517

DO - 10.1002/hep.22517

M3 - Article

C2 - 18846542

AN - SCOPUS:56149116412

VL - 48

SP - 1549

EP - 1557

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 5

ER -